Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719050 | 0.87 | SLC2A1 (0.51) | SLC2A1TOP2ASLC2A2CYP1A2CYP2C9 | |
| SCHEMBL17719043 | 0.86 | SLC2A1 (0.61) | SLC2A1SLC2A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16246753 | 0.84 | SLC2A1 (0.76) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719051 | 0.82 | SLC2A1 (0.61) | SLC2A1SLC2A2 | |
| SCHEMBL17719042 | 0.82 | SLC2A2 (0.70) | SLC2A1SLC2A2 | |
| SCHEMBL5318501 | 0.79 | MEN1 (0.58) | SLC2A1ALOX5KCNK3KCNK9MEN1 | |
| SCHEMBL17719163 | 0.74 | SLC2A1 (0.52) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL18963196 | 0.74 | KCNK3 (0.79) | KCNK3KCNK9 | |
| SCHEMBL17718924 | 0.73 | SLC2A1 (0.73) | SLC2A1SLC2A2 | |
| SCHEMBL4920109 | 0.72 | FASN (0.66) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | SLC2A1 6/4885ALOX5 3680/4885TOP2A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.